PART I Overview Novavax, Inc., together with our wholly owned subsidiaries, tackles some of the worlds most pressing health challenges with its scientific expertise in vaccines and its proven technology platform, including its Matrix-M adjuvant and protein-based nanoparticles. Our corporate growth strategy focuses on maximizing the impact of our cutting-edge technology by forging partnerships for our Matrix-M adjuvant and research and development (R&D) assets while maintaining a lean and focused...
Q2 FY2026 — expected 2026-08-19
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-02-26 | 2025-12-31 | 0001000694-26-000007 | EDGAR | 92K words |
| 2025-02-27 | 2024-12-31 | 0001000694-25-000004 | EDGAR | — |
| 2024-02-28 | 2023-12-31 | 0001000694-24-000007 | EDGAR | — |
| 2023-02-28 | 2022-12-31 | 0001000694-23-000005 | EDGAR | — |
| 2022-03-01 | 2021-12-31 | 0001000694-22-000004 | EDGAR | — |
| 2021-03-01 | 2020-12-31 | 0001000694-21-000004 | EDGAR | — |
| 2020-03-11 | 2019-12-31 | 0001104659-20-031944 | EDGAR | — |
| 2019-03-18 | 2018-12-31 | 0001144204-19-014640 | EDGAR | — |
| 2018-03-14 | 2017-12-31 | 0001144204-18-014686 | EDGAR | — |
| 2017-02-27 | 2016-12-31 | 0001144204-17-011334 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-11-06 | 2025-09-30 | 0001000694-25-000046 | EDGAR | 32K words |
| 2025-08-06 | 2025-06-30 | 0001000694-25-000029 | EDGAR | — |
| 2025-05-08 | 2025-03-31 | 0001000694-25-000021 | EDGAR | — |
| 2024-11-12 | 2024-09-30 | 0001000694-24-000043 | EDGAR | — |
| 2024-08-08 | 2024-06-30 | 0001000694-24-000035 | EDGAR | — |
| 2024-05-10 | 2024-03-31 | 0001000694-24-000031 | EDGAR | — |
| 2023-11-09 | 2023-09-30 | 0001000694-23-000055 | EDGAR | — |
| 2023-08-08 | 2023-06-30 | 0001000694-23-000047 | EDGAR | — |
| 2023-05-09 | 2023-03-31 | 0001000694-23-000040 | EDGAR | — |
| 2022-11-09 | 2022-09-30 | 0001000694-22-000024 | EDGAR | — |
| 2022-08-09 | 2022-06-30 | 0001000694-22-000016 | EDGAR | — |
| 2022-05-10 | 2022-03-31 | 0001000694-22-000009 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-02-26 | 0001000694-26-000011 | EDGAR | 5K words |
| 2026-01-20 | 0001104659-26-004785 | EDGAR | — |
| 2026-01-12 | 0001104659-26-002725 | EDGAR | — |
| 2025-11-06 | 0001000694-25-000048 | EDGAR | — |
| 2025-11-04 | 0001104659-25-105818 | EDGAR | — |
| 2025-10-22 | 0001104659-25-101390 | EDGAR | — |
| 2025-10-07 | 0001104659-25-097317 | EDGAR | — |
| 2025-08-27 | 0001104659-25-084053 | EDGAR | — |
| 2025-08-27 | 0001104659-25-084049 | EDGAR | — |
| 2025-08-21 | 0001104659-25-081160 | EDGAR | — |
315 total filings indexed. 283 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001000694 |
| Ticker | NVAX |
| Exchange | Nasdaq |
| SIC | 2836: Biological Products, (No Diagnostic Substances) |
| Incorporated | DE |
| Website | https://www.novavax.com |
| Listed | 1995-12-05 |
This is the free public profile. For structured JSON with full provenance chain, use the API:
JSON Profile Stock Quote AI Readiness Report